COVID-19

[Signal Transduction and Targeted Therapy] Scientists reported on the development of a highly efficacious mRNA vaccine, SW0123 that is composed of sequence-modified mRNA encoding the full-length SARS-CoV-2 Spike protein packaged in core–shell structured lipopolyplex nanoparticles.

[Scientific Reports] Researchers introduced a model of the immune response to a virus. This was based upon the same sort of mean-field dynamics as used in epidemiology. However, in place of the location, clinical status, and other attributes of people in an epidemiological model, researchers considered the state of a virus, B and T-lymphocytes, and the antibodies they generated.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists showed that the translation inhibition activity of NSP14 was conserved in human coronaviruses. NSP14 was required for virus replication through contribution of its exoribonuclease and N7-methyltransferase activities.

[Onconova Therapeutics, Inc. (Globe Newswire, Inc.)] Onconova Therapeutics, Inc. announced that the first patient has been dosed in the US Phase I clinical trial of ON 123300, the company’s novel multi-kinase inhibitor, for HR+ HER 2- metastatic breast cancer patients who are refractory to, or progressing on, currently approved CDK 4/6 inhibitors.

[Nature Communications] Reesarchers highlighted a balanced anti-inflammatory antiviral response associated with a better outcome and persisting TRM cells as important for future protection against SARS-CoV-2 infection.

[Scientific Reports] Researchers clustered 277 cell lines and revealed distinct COVID-19 transcriptomic signatures of the cells with similar phenotypes that defines their suitability for COVID-19 research.